Table 1.

Proportion of molecular aberrations in the PI3K pathway by tumor type UNK, unknown

Molecular Aberration	Endometrial		Ovarian					Cervical
	Endometrioid	Non- endometrioid	High Grade Serous	Low Grade Serous	Clear Cell	Endometrioid	Mucinous	Squamous	Adenocarcinoma
PTEN protein loss	80	5	45	rare	24		rare	13	3.6
PTEN mutation	43	0–11	rare	<1	3– 20	5–33	2	6	rare
PI3KCA mutation	30–40	20	rare	2	20– 34	20	13	14–48	14–25
PI3KCA amplification	2–4	46	68	20	20	20	UNK	UNK	UNK
AKT mutation	2–3	0	rare	rare	UN K	UNK	UNK	UNK	UNK
PI3KR1 mutation	43	12	UNK	UNK	UN K	UNK	UNK	UNK	UNK
ARID1A mutation	34	0	UNK	UNK	29	32	UNK	UNK	UNK
IGF-IR over- expression	75	rare	25	75	UN K	UNK	UNK	UNK	UNK